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Background: The epidermal growth factor receptor (EGFR)/RAS/RAF/MEK/MAPK pathway is an important pathway
in the carcinogenesis, invasion and metastasis of colorectal cancers (CRCs). We conducted a retrospective study to
determine the prognostic values of EGFR expression and KRAS mutation in patients with metastatic CRC (mCRC)
based on synchronous or metachronous status.
Methods: From October 2002 to March 2012, 205 patients with mCRC were retrospectively analyzed; 98 were
found to have metachronous mCRC while 107 were found to have synchronous mCRC. The EGFR expressions were
determinate by IHC (immunohistochemistry) analysis and categorized 1+ (weak intensity), 2+ (moderate intensity),
and 3+ (strong intensity). Genomic DNA was isolated from frozen primary CRC tissues and direct sequencing of
KRAS was performed. The clinicopathological features of these mCRC patients were retrospectively investigated
according to EGFR expression and KRAS mutation status. Moreover, we analyzed the prognostic values of EGFR
expression and KRAS mutation among these patients.
Results: Of the 205 patients with mCRC, EGFR expression was analyzed in 167 patients, and positive EGFR
expression was noted in 140 of those patients (83.8%). KRAS mutation was investigated in 205 patients and
mutations were noted in 88 of those patients (42.9%). In patients with metachronous mCRC, positive EGFR
expression was significantly correlated with well-and moderately-differentiated tumors (P = 0.028), poorer
disease-free survival (DFS) (P < 0.001), and overall survival (OS) (P < 0.001). Furthermore, positive EGFR expression was
a significant independent prognostic factor of DFS (P = 0.006, HR: 4.012, 95% CI: 1.130–8.445) and OS (P = 0.028,
HR: 3.090, 95% CI: 1.477–10.900) in metachronous mCRC patients. KRAS mutation status was not significantly related
to DFS and OS of patients with metachronous mCRC; likewise, KRAS mutation status was not significantly different
in the progression-free survival (PFS) and OS of patients with synchronous mCRC (all P > 0.05).
Conclusions: The present study demonstrated that EGFR expression has prognostic value only for patients with
metachronous mCRC. However, KRAS mutation did not have prognostic value in patients with metachronous or
synchronous mCRC.
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Colorectal cancer (CRC) is the third most common cancer
and the third leading cause of cancer death in the United
States where an estimated 142,820 newly diagnosed cases
of CRC and an estimated 50,830 cancer deaths from CRC
were reported in 2013 [1]. In Taiwan, CRC is the most
common cancer type, having increased rapidly in preva-
lence, and the third leading cause of cancer-related death
as of 2012. The incidence of CRC was 32.38 per 100,000
(7,213 new diagnoses of CRC) in 2000 and 60.72 per
100,000 (14,040 new diagnoses of CRC) in 2010 [2]. In
Taiwan, 5131 people died from CRC in 2012 and the death
rate was 22.0 per 100,000 [2]. The prognoses of metastasis
colorectal cancer (mCRC) have improved in the past dec-
ade, with the median overall survival (OS) rate increasing
from 12 months to more than 24 months [3,4]. These
improvements are considered to be a result of the devel-
opment of combinations of standard chemotherapy, in-
cluding fluoropyrimidine/folinic acid, irinotecan (FOLFIRI),
and oxaliplatin (FOLFOX), and the introduction of new
targeted biological agents such as cetuximab, panitumu-
mab, and bevacizumab.
EGFR is a 170-KDa transmembrane receptor with an
intracellular tyrosine kinase domain. EGFR is a member
of the ErbB receptor family. After EFGR is bounded by
EGF, EFGR forms a functionally active dimer (homodimer
or heterodimer) that causes phosphorylation of tyrosine
kinases in the intracellular domain of EGFR. Subsequently,
complex intracellular signals to the cytoplasm and then
to the nucleus are triggered by this phosphorylation [5].
Two major downstream signaling pathways are mediated
by EGFR: the RAS/RAF/MEK/MAPK pathway and the
PI3K–Akt pathway. The functions of the EGFR/RAS/
RAF/MEK/MAPK pathway are associated with gene tran-
scription, cell-cycle progression from the G1 phase to the
S phase, and cell proliferation. Moreover, the EGFR/RAS/
RAF/MEK/MAPK pathway has also been reported to play
a critical role in the carcinogenesis, migration, invasion,
and metastasis of CRC [5]. EGFR overexpression was pre-
viously thought to be associated with more advanced dis-
ease and worse prognoses. The prognostic value of EGFR
in CRC has been investigated extensively, but it remains
controversial [6-10]. Although KRAS mutation has been
studied for the predictive value of tumor response to anti-
EGFR treatment and also has been confirmed to be the
highly predictive of resistance to anti-EGFR treatment
[11-18], the prognostic value of KRAS mutation in syn-
chronous and metachronous mCRC remains controversial
[18-28]. Therefore, we conducted a retrospective study to
evaluate the prognostic value of EGFR expression and
KRAS mutation in patients with synchronous or meta-
chronous mCRC. Synchronous metastasis was defined as
metastatic disease at the time of the primary CRC diagno-
sis. Metachronous metastasis was defined as the absenceof metastatic disease at the time of initial CRC diagnosis
with metastatic disease developing more than 3 months
after resection of the primary CRC.Methods
Patients
This retrospective study included 205 patients with his-
tologically proven synchronous or metachronous mCRC
who received surgical treatment from a single-institution
between October 2002 and July 2012. The present study
was approved by the Institutional Review Board of the
Kaohsiung Medical University Hospital. Patients’ clinical
outcomes and survival statuses were regularly followed
up. Available variables included: age of diagnosis, sex,
tumor location, histological type, TNM classification,
vascular invasion, perineural invasion, and preoperative
and postoperative serum level of CEA. The TNM classi-
fication was defined according to the criteria of the
American Joint Commission on Cancer/International
Union Against Cancer (AJCC/UICC) [29]. All patients
were followed up until their deaths, their last follow-up,
or December 31, 2012. Overall survival (OS) was de-
fined as the time from the date of primary treatment to
the date of death from any cause or until the date of the
last follow-up. Disease-free survival (DFS) for patients
with metachronous mCRC was defined as the time from
the date of primary treatment to the date of diagnosis
for recurrence or metastatic disease or to the date of the
last follow-up. Progress-free survival (PFS) for patients
with synchronous mCRC was defined as the time from
the date of primary treatment to the date of tumor pro-
gression or to the date of death from any cause, or to
the date of the last follow-up.Immunohistochemical analysis for EGFR expression
Formalin-fixed and paraffin-embedded tissue blocks were
cut into 3 μm sections and deparaffinized, rehydrated, and
autoclaved at 121°C for 5 min in Target Retrieval solution
(Dako, Glostrup, Denmark), pH 6.0, to retrieve antigens.
Endogenous peroxidase was blocked by 3% hydrogen
peroxide for 5 min at room temperature. After washing
with a Tris buffer solution, the sections were incubated
with EGFR for 1 hour at room temperature. Then,
DAKO REAL EnVision Detection System-HRP (DAKO,
Glostrup, Denmark) was applied for 30 minutes at room
temperature. Finally, sections were incubated in 3′, 3-
diaminobenzidine for 5 minutes, followed by Mayer’s
hematoxylin counterstaining. Dehydration was performed
through two changes of 95% ethanol and two changes of
100% ethanol, and the samples were cleared in three
changes of xylene and then mounted. Negative controls
were obtained by replacing the primary antibody with
non-immune serum. Immunoreactivity of EGFR was
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blinded to patient outcome.
Expression patterns of EGFR were determined in a
semi-quantitative manner by light microscopy. Immu-
noreactivity for EGFR (membrane staining) was cate-
gorized in accordance with the presence of tumor cell
staining and staining intensity. The intensity of EGFR
immunoreactivity was scored with a 3-tier system as
follow [7,30]: 1+ (weak intensity); 2+ (moderate inten-
sity); and 3+ (strong intensity) (Figure 1). Negative
EGFR expression means absence of membrane staining
above background in all tumor cells. Positive EGFR ex-
pression is defined as any IHC (immunohistochemistry)
complete or incomplete membrane staining of tumor cells,
including intensity 1+, 2+ or 3 +.DNA extraction and direct sequencing of KRAS
Genomic DNA was isolated from frozen primary CRC
tissues, using proteinase-K (Stratagene, La Jolla, CA, USA)
digestion and the phenol/chloroform extraction procedure
according to the method outlined by Sambrook et al. [31].
The designed sequences of oligonucleotide primers for
exons 2 and 3 of the KRAS and the operational procedure
of direct sequencing were based on those of our previously
study [18,32].Figure 1 Immunohistochemical staining of EGFR in CRC. A. negative e
staining) (magnification, 100X). C. 2+ (moderate intensity of membrane sta
staining) (magnification, 100X).Statistical analysis
All data were statistically analyzed using the Statistical
Package for the Social Sciences, version 19.0 (SPSS Inc.,
Chicago, IL, USA). The correlation between clinicopatho-
logical features and EGFR expression or KRAS mutation
was compared using a Chi-square test (for categorical var-
iables) and Student t-test (for continuous variables). The
Cox proportional-hazards model was used for univariate
and multivariate analyses to identify the independent
prognostic factors for OS, DFS and PFS. OS, DFS, and
PFS were calculated by the Kaplan-Meier method, and the
differences in survival rates were analyzed by the log-rank
test. A P value less than 0.05 was considered to be statisti-
cally significant.Results
Characteristics of patients with mCRC
Of the 205 patients with mCRC, 98 patients (47.8%) were
metachronous and 107 patients (52.2%) were synchron-
ous. The mean age of the 205 patients was 61.0 ± 12.8
(range, 29–86) years of age. There were 120 males and 85
females. The median follow-up time for the 205 patients
was 30.2 ± 20.9 (range, 1–137.3) months. Immunohisto-
chemical analyses for EGFR expression were performed in
174 patients and positive expression was noted in 140 ofxpression (magnification, 100X). B. 1+ (weak intensity of membrane
ining) (magnification, 100X). D. 3+ (strong intensity of membrane
Table 1 Baseline characteristics of metachronous metastatic colorectal cancer patients by EGFR expression and KRAS
mutation status
Characteristic EGFR positive (%) EGFR negative (%) P value KRAS WTa (%) KRAS Mutb (%) P value
N = 67 (79.8%) N = 17 (20.2%) N = 54 (55.1%) N = 44 (44.9%)
Age (years, mean ± SD) 59.13 ± 10.49 64.41 ± 12.13 0.076 59.98 ± 10.21 59.18 ± 13.81 0.743
Gender 0.547 0.011
Male 37 (55.2) 8 (47.1) 36 (66.7) 18 (40.9)
Female 30 (44.8) 9 (52.9) 18 (33.3) 26 (59.1)
Tumor size 0.04 0.910
≥5 cm 18 (26.9) 9 (53.9) 19 (35.2) 15 (34.1)
<5 cm 49 (73.1) 8 (47.1) 35 (64.8) 29 (65.9)
Tumor location 0.518 0.130
Colon 45 (67.2) 10 (58.8) 30 (49.2) 31 (34.0)
Rectum 22 (32.8) 7 (41.2) 24 (64.9) 13 (66.0)
Histology 0.044 0.688
Well 1 (2.5) 1 (5.9) 1 (1.9) 1 (2.3)
Moderately 62 (92.5) 12 (70.6) 45 (83.3) 39 (88.6)
Poorly 4 (5.0) 4 (23.5) 8 (14.8) 4 (9.1)
Histology 0.028 0.390
Well + Moderately 63 (94.0) 13 (76.5) 46 (85.2) 40 (90.9)
Poorly 4 (6.0) 4 (23.5) 8 (14.8) 4 (9.1)
AJCC stage (Initial diagnosis) 0.928 0.993
I 6 (9.0) 2 (11.8) 5 (9.3) 4 (9.1)
II 19 (28.4) 5 (29.4) 14 (25.9) 11 (25.0)
III 42 (62.6) 10 (58.8) 35 (64.8) 29 (65.9)
Tumor depth 0.531 0.344
T1 0 (0) 0 (0) 1 (1.9) 0 (0.0)
T2 8 (11.9) 2 (11.8) 4 (7.4) 6 (13.6)
T3 48 (71.7) 14 (82.3) 39 (72.2) 34 (77.3)
T4 11 (16.4) 1 (5.9) 10 (18.5) 4 (9.1)
Lymph nodes metastases 0.755 0.401
N0 25 (37.3) 7 (41.2) 19 (35.2) 15 (34.1)
N1 30 (44.8) 6 (35.3) 21 (38.9) 22 (50.0)
N2 12 (17.9) 4 (23.5) 14 (25.9) 7 (15.9)
Retrived LNc 14.50 ± 8.70 16.00 ± 7.18 0.594 14.98 ± 9.98 15.69 ± 9.26 0.742
Vascular invasion 0.701 0.053
Yes 23 (34.3) 5 (29.4) 25 (46.3) 12 (27.3)
No 44 (65.75) 12 (70.6) 29 (53.7) 32 (72.7)
Perineurial invasion 0.395 0.624
Yes 23 (34.3) 4 (23.5) 21 (38.9) 15 (34.1)
No 44 (65.75) 13 (76.5) 33 (61.1) 29 (65.9)
Pre-op serum CEA level 0.598 0.482
≥5 ng/ml 27 (40.3) 7 (41.2) 24 (44.4) 21 (47.7)
<5 ng/ml 40 (59.7) 10 (58.8) 30 (55.6) 23 (52.3)
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Table 1 Baseline characteristics of metachronous metastatic colorectal cancer patients by EGFR expression and KRAS
mutation status (Continued)
Post-op serum CEA level 0.356 0.097
≥5 ng/ml 21 (31.3) 4 (23.5) 20 (37.0) 10 (22.7)
<5 ng/ml 46 (68.7) 13 (76.5) 34 (63.0) 34 (77.3)
Overall survival (months) 36.72 ± 18.68 62.51 ± 31.86 <0.001 42.54 ± 28.07 37.41 ± 17.23 0.293
Disease-free survival (months) 14.48 ± 9.91 34.27 ± 18.58 <0.001 18.38 ± 15.86 16.43 ± 10.58 0.487
aWT: wild type; bMut: mutation; cLN: lymph node.
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ated in 205 patients, and mutation was noted in 88 of
those patients (42.9%).
Characteristics of patients with metachronous mCRC
The clinical and pathological data regarding the 98
patients with metachronous mCRC are summarized in
Table 1. Immunohistochemical analyses for EGFR ex-
pression were performed in 84 patients, and positive
EGFR expression was noted in 67 of those patients
(79.8%). There were no significant differences in mean
ages, gender, tumor location, AJCC/UICC cancer stage,
retrieved lymph node number, vascular invasion, peri-
neural invasion, pre-operative serum CEA level, and
post-operative serum CEA level between patients with
positive EGFR expression and those with negative
EGFR expression. However, OS (36.72 vs. 62.51 months,
P < 0.001) and DFS (14.48 vs. 34.27 months, P < 0.001)
rates of patients with positive EGFR expression were sig-
nificantly poorer than those of patients with negative
EGFR expression.
KRAS mutation status was evaluated in 98 patients
and mutation was noted in 44 of those patients (44.9%).
There were no significant differences in mean ages,
tumor location, histological type, AJCC/UICC cancer
stage, retrieved lymph node number, vascular invasion,
perineural invasion, pre-operative serum CEA level, and
post-operative serum CEA level between patients with
wild-type KRAS and those with mutated KRAS. OS
(42.54 vs. 37.41 months, P = 0.293) and DFS (18.38 vs.
16.43 months, P = 0.487) were not significantly different
between patients with wild-type KRAS and those with
mutated KRAS.
Characteristics of patients with synchronous mCRC
The clinical and pathological data regarding the 107
patients with synchronous mCRC are summarized in
Table 2. Immunohistochemical analyses for EGFR expres-
sion were performed in 90 patients, and a positive EGFR
expression was noted in 73 patients (88.0%). There were
no significant differences in mean ages, gender, tumor
location, histological type, tumor depth, lymph node
metastasis, retrieved lymph node number, vascular inva-
sion, perineural invasion, pre-operative serum CEAlevel, and post-operative serum CEA level between
patients with positive EGFR expression and those with
negative EGFR expression. Moreover, OS (22.08 vs.
24.70 months, P = 0.523) and PFS (9.65 vs. 7.44 months,
P = 0.417) were not significantly different between pa-
tients with positive EGFR expression and those negative
EGFR expression. The differences of clinical and patho-
logical data regarding the patients with metachronous
mCRC and the patients with synchronous mCRC are
summarized in Additional file 1: Table S1.
KRAS mutation status was evaluated in 107 patients,
and mutation was noted in 44 of those patients (41.1%).
There were no significant differences in mean ages, gen-
der, tumor location, histological type, tumor depth, lymph
node metastasis, retrieved lymph node number, vascular
invasion, perineural invasion, pre-operative serum CEA
level, and post-operative serum CEA level between pa-
tients with wild-type KRAS and those with mutated KRAS.
Moreover, OS (23.04 vs. 18.74 months, P = 0.074) and PFS
(10.22 vs. 7.95 months, P = 0.101) were also not signifi-
cantly different.
Univariate and multivariable analyses of survival impact
of EGFR expression and KRAS mutation in patients with
metachronous mCRC
The univariate and multivariate analyses were performed
to investigate independent prognostic factors for OS and
DFS in patients with metachronous mCRC using the
Cox proportional-hazards model (Table 3). Positive
EGFR expression was demonstrated to be independent
negative prognostic factors for OS (P = 0.028; HR, 3.090;
95% CI, 1.130–8.445) and DFS (P = 0.006; HR, 4.012;
95% CI, 1.477–10.900). However, KRAS mutation was
not a significant prognostic factor for OS (P = 0.140; HR,
1.815; 95% CI, 0.823–4.004) and DFS (P = 0.260; HR,
1.440; 95% CI, 0.656–0.081). The Kaplan-Meier survival
analysis also demonstrated that patients with positive
EGFR expressions had worse OS (P = 0.003) and DFS
(P < 0.001) (Figure 2A and 2B). The median OS times of
patients with positive EGFR expression and those with
negative EGFR expression were 49.50 and 76.20 months
(P = 0.003; 95% CI, 41.223–57.777 and 52.175–99.920),
respectively. The 5-year OS rates of patients with posi-
tive EGFR expression and those with negative EGFR
Table 2 Baseline characteristics of synchronous metastatic colorectal cancer patients by EGFR expression and KRAS
mutation status
Characteristic EGFR positive (%) EGFR negative (%) P value KRAS WTa (%) KRAS Mutb (%) P value
N = 73 (88.0%) N = 17 (12.0%) N = 63 (58.9%) N = 44 (4119%)
Age (years, mean ± SD) 61.14 ± 11.81 65.80 ± 8.05 0.231 61.83 ± 10.49 61.86 ± 13.93 0.987
Gender 0.787 0.119
Male 47 (64.4) 6 (60.0) 35 (55.6) 31 (70.5)
Female 26 (35.6) 4 (40.0) 28 (44.4) 13 (29.5)
Tumor size 0.047 0.134
≥5 cm 39 (53.4) 2 (20.0) 28 (44.4) 26 (59.1)
<5 cm 34 (46.6) 8 (80.0) 35 (55.6) 18 (40.9)
Tumor location 0.055 0.098
Colon 62 (84.9) 6 (60.0) 46 (73.0) 38 (86.4)
Rectum 11 (15.1) 4 (40.0) 17 (27.0) 6 (13.6)
Histology 0.862 0.873
Well 2 (2.7) 0 (00.0) 2 (3.2) 1 (2.3) 0.873
Moderately 58 (79.5) 8 (80.0) 49 (77.8) 36 (81.8)
Poorly 13 (17.8) 2 (20.0) 12 (19.0) 7 (15.9)
Histology 0.866 0.676
Well + Moderately 60 (82.2) 8 (80.0) 51 (81.0) 37 (84.1)
Poorly 13 (17.8) 2 (20.0) 12 (19.0) 7 (15.9)
Tumor depth 0.792 0.734
T1 1 (1.4) 0 (0.0) 1 (1.6) 0 (0.0)
T2 3 (4.1) 1 (10.0) 3 (4.8) 3 (6.8)
T3 48 (65.7) 7 (70.0) 45 (71.4) 29 (65.9)
T4 21 (28.8) 2 (20.0) 14 (22.2) 12 (27.3)
Lymph nodes metastases 0.407 0.824
N0 17 (23.2) 4 (40.0) 14 (22.2) 10 (22.7)
N1 28 (38.4) 2 (20.0) 25 (39.7) 15 (34.1)
N2 28 (38.4) 4 (40.0) 24 (38.1) 19 (43.2)
Retrived LNc 17.09 ± 8.04 14.40 ± 5.85 0.313 16.31 ± 8.36 16.25 ± 8.17 0.971
Vascular invasion 0.756 0.863
Yes 33 (45.2) 4 (40.0) 29 (46.0) 21 (47.7)
No 40 (54.8) 6 (60.0) 34 (54.0) 23 (52.3)
Perineurial invasion 0.968 0.539
Yes 36 (49.3) 5 (50.0) 32 (50.8) 25 (56.8) 0.539
No 37 (50.7) 5 (50.0) 31 (49.2) 19 (43.2)
Pre-op serum CEAb level 0.496 0.827
≥5 ng/ml 58 (79.5) 7 (70.0) 49 (77.8) 35 (79.5)
<5 ng/ml 15 (20.5) 3 (30.0) 14 (22.2) 9 (20.5)
Post-op serum CEAb level 0.568 0.799
≥5 ng/ml 21 (28.8) 4 (40.0) 43 (68.3) 29 (65.9)
<5 ng/ml 46 (71.2) 6 (60.0) 20 (31.7) 15 (34.1)
Overall survival (months) 22.08 ± 12.38 24.70 ± 9.91 0.523 23.04 ± 12.62 18.74 ± 11.39 0.074
Progression-free survival (months) 9.65 ± 7.44 11.66 ± 6.16 0.417 10.22 ± 7.14 7.95 ± 6.75 0.101
aWT: wild type; bMut: mutation; cLN: lymph node.
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Table 3 Univariate and multivariable analysis of prognostic indicators on overall survival and disease-free survival for
metachronous metastatic colorectal cancer patients (N = 98)
Parameters Overall survival Disease-free survival
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age (years) 0.691 (0.376–1.271) 0.235 0.678 (0.303–1.515) 0.343 0.829 (0.453–1.518) 0.544 0.990 (0.439–2.231) 0.980
(≥65 vs <65)
Sex 0.933 (0.525–1.658) 0.933 0.848 (0.409–1.755) 0.656 1.018 (0.574–1.806) 0.951 0.912 (0.433–1.921) 0.808
(Male vs Female)
Location 0.824 (0.454–1.495) 0.523 0.985 (0.449–2.164) 0.971 0.764 (0.421–1.388) 0.378 1.033 (0.477–2.237) 0.935
Rectum vs Colon
Tumor size 0.897 (0.490–1.643) 0.725 1.088 (0.512–2.310) 0.826 0.896 (0.489–1.641) 0.722 1.043 (0.471–2.311) 0.917
(≥5 cm vs <5 cm)
Tumor depth 0.972 (0.412–2.295) 0.949 0.699 (0.238–2.050) 0.514 1.047 (0.443–2.473) 0.917 1.030 (0.356–2.980) 0.956
T3 + T4 vs T1 + T2
LN metastasis 1.062 (0.588–1.923) 0.844 0.989 (0.448–2.181) 0.570 1.090 (0.604–1.965) 0.776 0.813 (0.364–1.817) 0.614
Yes vs No
Histology 605 (0.216–1.695) 0.339 0.628 (0.126–3.128) 0.766 0.625 (0.223–1.7448) 0.370 1.044 (0.210–5.200) 0.958
PD vs MD +WD
AJCC stage 1.062 (0.586–1.923) 0.844 1.090 (0.604–1.965) 0.776
III vs I&II
Vascular invasion 1.643 (0.921–2.932) 0.093 1.160 (0.519–2.629) 0.707 1.555 (0.869–2.782) 0.137 1.297 (0.549–3.068) 0.553
Yes vs No
Perineurial invasion 1.411 (0.785–2.536) 0.250 1.107 (0.470–2.611) 0.816 1.312 (0.731–2.354) 0.363 0.933 (0.369–2.361) 0.884
Yes vs No
Pre-op CEA (ng/ml) 0.991 (0.530–1.851) 0.977 0.680 (0.289–1.603) 0.378 1.147 (0.616–2.134) 0.666 0.901 (0.377–2.154) 0.815
≥5/ vs <5
Post-op CEA (ng/ml) 1.432 (0.763–2.688) 0.264 1.414 (0.561–3.562) 0.462 1,479 (0.788–2.779) 0.223 1.187 (0.454–3.101) 0.727
≥5 vs <5
EGFR expression 3.577 (1.464–8.741) 0.005 3.090 (1.130–8.445) 0.028 4.609 (1.864–11.396) 0.001 4.012 (1.477–10.900) 0.006
Positive vs Negative
KRAS status 1.249 (0.690–2.260) 0.462 1.815 (0.823–4.004) 0.140 1.066 (0.597–1.904) 0.829 1.440 (0.656–.081) 0.260
Mut vs WT
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DFS times of patients with positive EGFR expression and
those with negative EGFR expression were 20.96 and
50.17 months (P < 0.001; 95% CI, 17.216–24.708 and
38.822–61.510), respectively. The 3-year DFS rates of pa-
tients with positive EGFR expression and those with nega-
tive EGFR expression were 16% and 51%, respectively.
The Kaplan-Meier survival analysis demonstrated no
significant difference between patients with wild-type
KRAS and those with mutated KRAS in terms of OS
(P = 0.461) and DFS (P = 0.783) (Figure 2C and 2D).
The median OS times of patients with wild-type KRAS and
those with mutated KRAS were 66.10 and 50.30 months
(P = 0.461; 95% CI, 39.430–92.770 and 40.770–59.830), re-
spectively. The median DFS times of patients with wild-type KRAS and those with mutated KRAS were 37.90
and 22.80 months (P = 0.783; 95% CI, 11.120–44.680
and 14.470–31.130), respectively. Furthermore, we ana-
lyzed the OS and DFS of patients with wild-type KRAS
(N = 54), mutated KRAS codon 12 (N = 32), and mu-
tated KRAS codon 13 (N = 12). No significant differ-
ence was noted in terms of OS (P = 0.656) and DFS
(P = 0.977) (Figures 2E and 2F).
Univariate and multivariable analyses of survival impact
of EGFR expression and KRAS mutation in patients with
synchronous mCRC
Univariate and multivariate analyses were performed to
investigate the independent prognostic factors for OS
and PFS in patients with synchronous mCRC using the
No. at risk
WT    54   51   38   27   19  15   10    2     2     2 
MUT  44  44   31   23   13    4      3
No. at risk
WT      54          26          16            7             3            2 
MUT   44           24            9            2             1
No. at risk
WT             54  51  38   27  19   15  10   2    2     2     1   1
Codon 12    32  32  23  17   11     3    2  
Codon 13    12  12    8    6     2     1    1
No. at risk
WT             54          27        16            7            3           2    
Codon 12   32         18          6  





Neg 17  17  16  13  11    9      8     2    2     2
Pos    68  65  47  33  18    9      4  
No. at risk
Neg 17        16          11           7           4            2 
Pos    68        31          13           2  
A B
1
Figure 2 The Kaplan-Meier survival curve for patients with metachronous mCRC. A. Overall survival stratified by EGFR expression. B. Disease-free
survival stratified by EGFR expression. C. Overall survival stratified by KRAS mutation status. D. Disease-free survival stratified by KRAS mutation status.
E. Overall survival stratified by wild-type KRAS, codon 12, and codon 13. F. Disease-free survival stratified by wild-type KRAS, codon 12, and codon 13.
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http://www.biomedcentral.com/1471-2407/13/599Cox proportional-hazards model (Table 4). No variable
was demonstrated to be an independent prognostic fac-
tor for OS and PFS in patients with synchronous mCRC.
The Kaplan-Meier survival analysis demonstrated no sig-
nificant difference between patients with positive EGFR
expression and those with negative EGFR expression in
terms of OS (P = 0.883) and PFS (P = 0.945) (Figure 3A
and 3B). The median OS times of patients with positive
EGFR expression and those with negative EGFR expres-
sion were 22.30 and 21.70 months (P = 0.883; 95% CI,
18.836–25.764 and 6.972–36.428), respectively. The me-
dian PFS times of patients with positive EGFR expres-
sion and those with negative EGFR expression were 8.20
and 11.70 months (P = 0.945; 95% CI, 6.356–10.044 and
8.425–14.975), respectively. In addition, the Kaplan-
Meier survival analysis demonstrated no significant dif-
ference between patients with wild-type KRAS and those
with mutated KRAS in terms of OS (P = 0.544) and PFS
(P = 0.555) (Figure 3C and 3D). The median OS times of
patients with wild-type KRAS and those with mutatedKRAS were 22.50 and 21.30 months (P = 0.544; 95% CI,
21.036–23.964 and 17.967–24.633), respectively. The
median PFS times of patients with wild-type KRAS and
those with mutated KRAS were 9.30 and 11.70 months
(P = 0.555; 95% CI, 7.395–11.205 and 4.696–18.704), re-
spectively. Furthermore, we analyzed the OS and DFS of
patients with wild-type KRAS (N = 63), mutated KRAS
codon 12 (N = 37), and mutated KRAS codon 13 (N = 7).
No significant difference was noted in terms of OS
(P = 0.656) and PFS (P = 0.977) (Figure 3E and 3F).
Discussion
Of the 205 patients analyzed in this study, 98 patients
had metachronous and 107 had synchronous mCRC.
Positive EGFR expression was found in 80.5% patients
through immunohistochemical analyses. The positive
rate of EGFR expression in CRC was reported to be 25%
to 82% [7]. KRAS mutation status was evaluated in 205
patients and mutation was noted in 88 of those patients
(42.9%), in concordance with the mutation rate of KRAS
Table 4 Univariate and multivariable analysis of prognostic indicators on overall survival and progress-free survival for
synchronous metastatic colorectal cancer patients (N = 107)
Parameters Overall survival Progression-free survival
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR P value
Age (years) 1.160 (0.697–1.929) 0.568 1.561 (0.812–2.999) 0.182 1.160 (0.697–1.929) 0.568 1.561 (0.812–2.999) 0.182
(≥65 vs <65)
Sex 1.096 (0.661–1.818) 0.722 1.617 (0.790–3.307) 0.188 1.096 (0.661–1.818) 0.722 1.617 (0.790–3.307) 0.188
(Male vs Female)
Location 0.668 (0.357–1.252) 0.209 0.540 (0.198–1.473) 0.229 0.668 (0.357–1.252) 0.209 0.540 (0.198–1.473) 0.229
Rectum vs Colon
Tumor size 1.281 (0.784–2.094) 0.323 1.344 (0.683–2.644) 0.392 1.281 (0.784–2.094) 0.323 1.344 (0.683–2.644) 0.392
(≥5 cm vs <5 cm)
Tumor depth 1.072 (0.333–3.456) 0.907 0.506 (0.107–2.396) 0.391 1.072 (0.333–3.456) 0.907 0.506 (0.107–2.396) 0.391
T3 + T4 vs T1 + T2
LN metastasis 0.955 (0.541–1.684) 0.873 0.957 (0.488–1.879) 0.899 0.955 (0.541–1.684) 0.873 0.957 (0.488–1.879) 0.899
Yes vs No
Histology 1.307 (0.678–2.520) 0.425 1.629 (0.655–4.052) 0.294 1.307 (0.678–2.520) 0.425 1.629 (0.655–4.052) 0.294
PD vs MD +WD
Vascular invasion 1.092 (0.670–1.779) 0.724 0.826 (0.425–1.605) 0.573 1.092 (0.670–1.779) 0.724 0.826 (0.425–1.605) 0.573
Yes vs No
Perineurial invasion 1.510 (0.918–2.485) 0.105 1.396 (0.740–2.636) 0.303 1.510 (0.918–2.485) 0.105 1.396 (0.740–2.636) 0.303
Yes vs No
Pre-op CEA (ng/ml) 1.243 (0.623–2.482) 0.538 1.216 (0.418–3.540) 0.719 1.243 (0.623–2.482) 0.538 1.216 (0.418–3.540) 0.719
≥5/ vs <5
Post-op CEA (ng/ml) 0.731 (0.425–1.257) 0.257 0.988 (0.412–2.370) 0.979 0.731 (0.425–1.257) 0.257 0.988 (0.412–2.370) 0.979
≥5 vs <5
EGFR expression 0.945 (0.443–2.016) 0.883 0.648 (0.281–1.492) 0.308 0.945 (0.443–2.016) 0.883 0.648 (0.281–1.492) 0.308
Positive vs Negative
KRAS status 1.167 (0.707–1.925) 0.546 1.051 (0.554–1.992) 0.879 1.167 (0.707–1.925) 0.546 1.051 (0.554–1.992) 0.879
Mut vs WT
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http://www.biomedcentral.com/1471-2407/13/599in CRC (35% to 42%) [19]. In our patients with meta-
chronous mCRC, EGFR expression was associated with
differentiation grade of the tumor, with more moderate
differentiation in patients with positive EGFR expression
(P = 0.028), in accordance with the report of Andreyev
et al. [25]. However, the association was not noted in
our synchronous mCRC patients. The association be-
tween histological grade and EGFR expression is still
controversial [6-8,33,34].
For the prognostic value of EGFR for patients with
metachronous mCRC, we have demonstrated EGFR as
an independent negative prognostic factor for OS and
DFS by multivariate Cox proportional-hazards model.
The Kaplan-Meier survival analysis also showed that pa-
tients with positive EGFR expression had worse OS and
DFS. Galizia et al. [7] have shown that there is strong as-
sociation between disease-specific survival and EGFRexpression status, and a more than 10-fold risk of cancer
related death in patients with positive EGFR expression
compared with patients with negative EGFR expression.
The difference was even stronger in patients with Duke’s
C and D colon cancer than in those with Duke’s A and
B colon cancer [7]. Ljuslinder et al. [6] have shown an
association between worse outcomes and higher EGFR
expression at invasive margin. Giralt et al. [9] evaluated
the relationship between prognosis and EGFR expression
in patients with locally advanced rectal cancer (LARC)
receiving preoperative radiotherapy, and they found that
the pathological response rate was lower in patients with
positive EGFR expression than in those with negative
EGFR expression. Azria et al. [10] conducted a similar
study to evaluate the prognostic impact of EGFR expres-
sion on locoregional recurrence in patients with LARC
receiving preoperative radiotherapy. The locoregional
No. at risk
WT         63       55        21        7          3          2         1 
MUT      44        29       12         4         1
No. at risk
WT         63                  16                     6              




Neg 10        10       4         2         
Pos     73        58     26         8          3        1           1
No. at risk
Neg 10                    3                     1 
Posi 73                  19                     7
BA
No. at risk
WT                  63        55        19        7          3         2           1     
Codon 12         37        22        11        3          1   
Codon 13           7          7          1        1     
No. at risk
WT              63                 16                     6              
Codon 12     37                   9                     3
Codon 13       7                    
E F
Figure 3 The Kaplan-Meier survival curve for patients with synchronous mCRC. A. Overall survival stratified by EGFR expression. B. Disease-free
survival stratified by EGFR expression. C. Overall survival stratified by KRAS mutation status. D. Disease-free survival stratified by KRAS mutation status.
E. Overall survival stratified by wild-type KRAS, codon 12, and codon 13. F. Disease-free survival stratified by wild-type KRAS, codon 12, and codon 13.
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http://www.biomedcentral.com/1471-2407/13/599recurrence rate was higher in patients with EFGR
extent ≧25% than in patients with EFGR ≦25% (20% vs.
7%). The locoregional recurrence-free survival rate at
2 years was 94% and 84%, respectively (P = 0.06). EFGR
extent ≧25% was a significant factor for locoregional
recurrence (P = 0.037; HR, 7.18; 95% CI, 1.17–46).
Theodoropoulos et al. [34] reported a significant asso-
ciation between high EGFR expression and advanced
T3 and T4 stages (P = 0.001), which implied that EGFR
overexpression was associated with tumor invasion. Fur-
thermore, they also demonstrated a trend between positive
EGFR expression and poorer OS. Deng et al. [35] reported
a significant association between high EGFR expression in
primary tumor and poorer OS (P = 0.046); however, the
association was not noted in stage IV patients, which is in
agreement with our present study. The association be-
tween EFGR expression and worse survival has also been
noted in other malignancies, such as gastric cancer
[36,37], esophageal cancer [38], and breast cancer [39]. In
contrast, Spano et al. [8] and McKay et al. [33] reported
no significant association between EGFR expression and
survival.Through the multivariate Cox proportional-hazards
analyses and Kaplan-Meier survival analysis used in this
study, KRAS mutation status was found not to be a sig-
nificant independent prognostic factor of OS, DFS, and
PFS for patients with metachronous mCRC and synchron-
ous mCRC. Roth et al. [19] reported a mutated rate of
37% of KRAS mutation from 1299 patients with stages II
and III colon cancer. No significant association between
survival (OS and relapse-free survival) and KRASmutation
status was demonstrated. Moreover, no difference was
noted between survival (OS and relapse-free survival) and
type of KRAS mutation stratified by condon 12 and 13 in
patients with stages II and III colon cancer, which is in
agreement with our analyses of patients with metachro-
nous mCRC. Rose et al. [20] assessed the survival impact
of KRAS mutation status in 110 patients with metachro-
nous and synchronous mCRC. The OS of patients with
metachronous and those with synchronous mCRC was
not influenced by KRAS mutation status (P = 0.55 and
0.37, respectively), which is also consistent with our
present study. Three studies [21-23] from Asia evaluating
the survival impact of KRAS mutation status in CRC
Huang et al. BMC Cancer 2013, 13:599 Page 11 of 12
http://www.biomedcentral.com/1471-2407/13/599patients also showed that there was no prognostic
value of KRAS mutation status for OS and PFS. Re-
cently, a systemic review and meta-analysis regarding
the prognostic value of KRAS mutation status demon-
strated that there was no association between KRAS
mutation status and the prognosis of patients with
CRC [24]. In contrast, 2 large collaborative Kirsten Ras
in Colorectal Cancer Collaborative Group (RASCAL)
studies [25,26] evaluated the prognostic role in CRC. It
was concluded in these studies that mutated KRAS
were significantly associated with an increased risk of
relapse and death and a significant association between
failure-free survival and G12V of mutated KRAS in
Duke’s C patients. Richman et al. [27] reported similar
PFS and worse OS in patients with mutated KRAS
compared to patients with wild-type KRAS. Roth et al.
indicated that the KRAS mutations were assessed by
each referring center according to three types of meth-
odologies, and meta-analysis results could be affected
by variations between trials [19]. In a meta-analysis
assessing the predictive and prognostic value of KRAS
mutations in CRC patients treated with cetuximab, it
was concluded that mCRC patients with mutated
KRAS could have worse PFS and OS when treated with
cetuximab [28].
To our best knowledge, this study is the first to evalu-
ate the prognostic values of EGFR expression and KRAS
mutation simultaneously in patients with metachronous
and synchronous mCRC. However, there are some limita-
tions to the present study. First, the present study is a
single-institution retrospective study. The study’s relatively
small sample size is another limitation. Third, the KRAS
mutation status was evaluated only as wild-type and mu-
tant (codon 12 and codon 13) and we did not analyze
other rare mutation types.Conclusion
In conclusion, we have demonstrated that EGFR ex-
pression has prognostic value only for patients with
metachronous mCRC, while having no such value for
patients with synchronous mCRC. Our data indicate
EGFR as an independent negative prognostic factor for
OS and DFS in patients with metachronous mCRC.
Analyzing EGFR expression may help identify high-risk
patients requiring more aggressive therapeutic modalities
in the setting of metachronous mCRC. However, KRAS
mutation did not have prognostic value for patients with
metachronous or synchronous mCRC.Additional file
Additional file 1: Table S1. Baseline characteristics of metachronous
and synchronous metastatic colorectal cancer patients.Abbreviations
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